Annexon, Inc. (ANNX) - Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers Annexon, Inc.'s Form 10-Q for the quarterly period ended June 30, 2026. Annexon is a clinical-stage biopharmaceutical company developing targeted immunotherapies for complement-mediated neuroinflammatory diseases. The company has no approved products and has not generated revenue from product sales. Key strategic priorities include advancing tanruprubart (for Guillain-Barré Syndrome) and vonaprument (for geographic atrophy in dry AMD).
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(55.3) million | $(99.5) million | $(103.5) million |
| Operating Expenses | $57.2 million | $103.3 million | $109.1 million |
| Cash & Short-Term Investments | $209.2 million (as of June 30, 2026) | ||
| Accumulated Deficit | $(1.02) billion (as of June 30, 2026) | ||
| Net Cash Used in Operating Activities | $(94.8) million (YTD 2026) |
Material Changes vs. Prior Period
- Net Loss Improvement: The net loss for the six months ended June 30, 2026, decreased by approximately $4.0 million (4%) compared to the same period in 2025, primarily due to reduced operating expenses.
- Operating Expenses: Total operating expenses decreased by $5.9 million (5%) year-over-year.
- R&D Expenses: Decreased by $10.0 million (11%), driven by lower contract manufacturing costs for tanruprubart and reduced personnel expenses.
- G&A Expenses: Increased by $4.1 million (24%), primarily due to higher consulting and professional services fees for corporate affairs.
- Interest Income: Interest and other income decreased by $1.8 million (33%) year-over-year due to lower average cash balances and interest rates.
- Capital Structure: The company raised approximately $63.8 million in net proceeds from equity issuances under its ATM programs during the first half of 2026. Additionally, 12.5 million pre-funded warrants were exercised for cashless shares.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management projects that existing cash and investments ($209.2 million) will fund operations into 2028. The company expects to continue incurring losses for the foreseeable future.
- Regulatory Milestones:
- Tanruprubart: A Marketing Authorization Application (MAA) is under review by the EMA. The company plans to submit a Biologics License Application (BLA) to the FDA in Q4 2026, pending data from the FORWARD study.
- Vonaprument: The Phase 3 ARCHER II trial is ongoing. The Month 15 primary endpoint is on track for Q4 2026. A Month 24 dual primary endpoint has been added.
- Subsequent Event (Debt Financing): On July 30, 2026, the company entered into a Loan and Security Agreement for up to $200 million. An initial tranche of $50 million was funded immediately. The loan bears interest at SOFR + 4.6% (minimum 7.6%) and matures in 2031/2032.
- Risks: Significant risks include the failure to obtain regulatory approval, the inability to raise additional capital on favorable terms, and the potential for clinical trial delays. The company is heavily dependent on third-party manufacturers and CROs.
Investor Verification Checklist
- Verify the status of the EMA MAA review for tanruprubart and the timeline for the FDA BLA submission in Q4 2026.
- Confirm the progress and enrollment rates of the vonaprument Phase 3 ARCHER II trial and the implications of the added Month 24 endpoint.
- Review the terms of the $200 million Loan and Security Agreement entered into in July 2026, specifically regarding covenants, interest rates, and milestone triggers for additional tranches.
- Monitor the company's cash burn rate relative to the $209.2 million cash balance to assess the validity of the "funding into 2028" projection.
- Assess the impact of the 2026 ATM program ($150 million capacity) on potential future dilution.